Management of Crohn's disease-new therapeutic approaches

    loading  Checking for direct PDF access through Ovid

Abstract

As long as the etiology of Crohn's disease is unknown, the development of new therapeutic modalities should take the increased understanding of the pathogenesis of the disease into consideration. Modulation of inflammatory mediators with specific lipoxygenase inhibitors or with specific platelet-activating factor receptor antagonists may be of value. Drugs such as ketotifen and synthetic somatostatin analogues, which inhibit the release of mediators from inflammatory cells, may be of benefit in view of their antisecretory and anti-inflammatory effects. The crucial role of free radicals in the pathogenesis of tissue injury advocates trial with potent scavengers, such as nitroxides, whereas there is still a place for further trials with antimycobacterial therapy.

Related Topics

    loading  Loading Related Articles